AssetMark’s Amylyx Pharmaceuticals AMLX Stock Holding History
Bought
Maintained
Sold
Other funds holding AMLX
SL
AssetMark's AMLX Position: Q3 2026 in Review
AssetMark opened a new position in Amylyx Pharmaceuticals (AMLX) in Q3 2026: 12 shares worth $349. The stake represents ﹤0.01% of the portfolio and ranks #3506 among its holdings.
147 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.
- AssetMark held 12 shares of Amylyx Pharmaceuticals worth $349 as of Q3 2026.
- Amylyx Pharmaceuticals was a new AssetMark position in Q3 2026.
- Amylyx Pharmaceuticals made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3506 holding.
- 147 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.